Tjalf Ziemssen - Concepedia

Author

Tjalf Ziemssen

University Hospital Carl Gustav Carus ORCID

Also Known As

Annette Wundes, Focke Ziemssen, Karl U. Bartz-Schmidt, Katja Akgün, Neurologische Universitätsklinik Dresden, T Ziemssen, T. Ziemssen, TJALF ZIEMSSEN, Tjalf Ziemssen, Tjalf ziemssen

707

Publications

17.4K

Citations

H-Index

232

Concepts

All Affiliations

University Hospital Carl Gustav Carus Technische Universität Dresden University of Tübingen Biogen (United States)Novartis (Germany)

About

Tjalf Ziemssen is an author at University Hospital Carl Gustav Carus specializing in medicine, neurology, and neuroimmunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	65	5.3K
2	Health Sciences	15	22	1.7K
3	Engineering	4	4	299
4	Nursing	2	2	40
5	Education	1	1	67

Tjalf Ziemssen

222

Publications

11.3K

Citations

H-Index

Page 1

	Year	Citations
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Ludwig Kappos, Amit Bar‐Or, Bruce Cree, The Lancet Neurological DisorderClinical NeurologyClinical TrialsSiponimod Versus PlaceboNeurological Monitoring	2018	896
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis J William L Brown, Alasdair Coles, Dana Horáková, JAMA	2019	511
Stroke-Induced Immunodepression Ulrich Dirnagl, Juliane Klehmet, Johann Braun, Stroke InflammationIschemic StrokeMedicineImmunologyBrain-immune Interaction	2007	451
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid Christian Schläger, Henrike Körner, Martin Krueger, Nature NeuroanatomyMedicineCerebrospinal FluidImmunologyCell Trafficking	2016	353
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension Raju Kapoor, Pei‐Ran Ho, Nolan Campbell, The Lancet Neurology Disease ProgressionNeurological DisorderImmunologyClinical TrialsNeurology	2018	327
Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy Tjalf Ziemssen Brain ImmunologyImmune RegulationImmunotherapyNeuroinflammationInflammation	2002	270
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial Diego Cadavid, Laura J. Balcer, Steven Galetta, The Lancet Neurology Acute Optic NeuritisOcular DiseaseOphthalmologyOptic NeuropathyEye Health	2017	264
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study Krzysztof Selmaj, David K.B. Li, Hans-Peter Hartung, The Lancet Neurology Relapsing-remitting Multiple SclerosisDisease ProgressionNeurological DisorderMedicineClinical Trials	2013	230
Spectral Analysis of Heart Rate Variability: Time Window Matters Kai Li, Heinz Rüdiger, Tjalf Ziemssen Frontiers in Neurology Electrophysiological EvaluationHeart FailureEngineeringCardiovascular DiseaseHrv Analysis	2019	193
The Activation Status of Neuroantigen-specific T Cells in the Target Organ Determines the Clinical Outcome of Autoimmune Encephalomyelitis Naoto Kawakami, Zhaoxia Li, Francesca Odoardi, The Journal of Experimental Medicine	2004	188

Page 1